In March 2025, the company declared new options for the direct-to-customer offering of its Wegovy weight loss drug. The company proven a completely new pharmacy, known as NovoCare, which would demand customers $499 every month for use of the drug, lower than 50 percent the price of the drug as a result of other pharmaceutical distribution networks.